 |
ImmunoGen, Inc. Appoints Suzanne Cadden as Vice President, Regulatory Affairs & Quality
Dec 17, 2009
|
7.9 KB |
| |
WALTHAM, Mass., Dec 17, 2009 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, announced today the appointment of Suzanne Cadden as Vice President of Regulatory Affairs & Quality. Ms. Cadden will be responsible for establishing - in conjunction with the Chief Medical Offi...
|
|
ImmunoGen, Inc. Announces Positive Trastuzumab-DM1 Clinical Data Reported at the San Antonio Breast Cancer Symposium
Dec 12, 2009
|
11.5 KB |
| |
WALTHAM, Mass., Dec 12, 2009 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of positive trastuzumab-DM1 (T-DM1) clinical data at the 32nd Annual San Antonio Breast Cancer Symposium (Abstract #710). T-DM1 comprises ImmunoGen's DM1 canc...
|
|
SAR3419 Phase I Study Results in non-Hodgkin's Lymphoma at ASH
Dec 7, 2009
|
14.3 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 7, 2009--
...
|
|
ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Multiple Myeloma
Dec 6, 2009
|
13.2 KB |
| |
WALTHAM, Mass., Dec 06, 2009 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment of relapsed and relapsed/refractory multiple myeloma (MM), including prolonged benefit in patients...
|
|
ImmunoGen, Inc. Announces Conference Call to Discuss Clinical Data Reported at Recent Medical Meetings
Dec 3, 2009
|
9.6 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 3, 2009--
...
|
|
ImmunoGen, Inc. Announces Clinical Data Presentations on Three TAP Compounds at Upcoming ASH Annual Meeting and Exposition
Nov 24, 2009
|
11.0 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 24, 2009--
...
|
|
ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Company's TAP Technology
Nov 19, 2009
|
9.6 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 19, 2009--
...
|
|
ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell Carcinoma
Nov 17, 2009
|
13.8 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 17, 2009--
...
|
|
ImmunoGen, Inc. Announces Election of Howard Pien to its Board of Directors and Other Results from its Annual Meeting of Shareholders
Nov 11, 2009
|
10.2 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 11, 2009--
...
|
|
ImmunoGen, Inc. Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Nov 10, 2009
|
9.8 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 10, 2009--
...
|
|
ImmunoGen, Inc. Reports First Quarter Fiscal Year 2010 Financial Results
Oct 29, 2009
|
30.1 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 29, 2009--
...
|
|
ImmunoGen, Inc. Announces Webcast of Presentation at the Oppenheimer 20th Annual Healthcare Conference
Oct 27, 2009
|
9.2 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 27, 2009--
...
|
|
ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2010 Financial Results
Oct 22, 2009
|
8.8 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 22, 2009--
...
|
|
ImmunoGen Announces Amgen has Licensed Rights to Use the Company's TAP Technology for a Solid Tumor Target
Sep 16, 2009
|
8.7 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Sep. 16, 2009--
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops
targeted anticancer products, today announced that Amgen Inc. has
licensed the...
|
|
ImmunoGen, Inc. Announces Webcast of Presentations at Two Investor Conferences
Sep 2, 2009
|
8.0 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Sep. 2, 2009--
ImmunoGen, Inc. (Nasdaq: IMGN) today announced the live webcast of its
corporate presentations at two upcoming investor conferences.
Its presenta...
|
|
ImmunoGen, Inc. Appoints Peter Williams as Vice President, Business Development
Aug 17, 2009
|
8.1 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 17, 2009--
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that
develops targeted anticancer therapeutics, today announced the
appointment of Peter Wi...
|
|
ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Aug 6, 2009
|
29.0 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 6, 2009--
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that
develops targeted anticancer therapeutics using its antibody expertise
and Targeted Antibody Pa...
|
|
ImmunoGen, Inc. Announces Webcast of Presentation at the 29th Annual Canaccord Adams Global Growth Conference
Aug 5, 2009
|
7.7 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 5, 2009--
ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at
the 29th Annual Canaccord Adams Global Growth Conference will
be w...
|
|
ImmunoGen Announces Encouraging New Clinical Data with the Company's IMGN901 Compound in the Treatment of Small-Cell Lung Cancer
Jul 31, 2009
|
16.0 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Jul. 31, 2009--
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that
develops targeted anticancer therapeutics using its Targeted Antibody
Payload (TAP) technology...
|
|
ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2009 Financial Results
Jul 30, 2009
|
7.8 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Jul. 30, 2009--
ImmunoGen, Inc. (Nasdaq:IMGN) will host a conference call at 4:30 pm ET
on Thursday, August 6, 2009 to discuss the Company’s financial resul...
|
|
|
